Why would you build a new lab in anticipation of an influx of Asian and Oz customers if you had no idea of when that might happen?
Printable View
Why would you build a new lab in anticipation of an influx of Asian and Oz customers if you had no idea of when that might happen?
I just do not understand why they did not / could not instigate this sort of clinical study years ago with the Vets, or whoever.. (KP not interested?)
Maybe we and the AUA would have the evidence now instead of forever reading "further evidence required" in the conclusions of independent reviews.
Or will this be a case of too small (n 426 patients) and too late/ slow to give Monitor the legs it needs now before Assure MDX et al gain traction?
Four (free?) tests each at time of monitoring cystoscopy over 12 -24 month period, then collate, review and review some more a few years after final test....), publish, could be looking at 4- 5 years before this will any help?
Good they have the cash reserves to keep plodding on
Making the call to back out on this, can't see the upcoming results making any significant increase to the SP.
Walking away with my original buy in, would have had a bit more in it if we hadn't taken part in the CR.
Its not rocket science to figure out that cash in large lumps, which has been lacking up until the large cash raise, may be required for clinical studies.
Other outfits proposing their particular brand of treatment will have the same costs involved in providing similar data and may take just as long to get it.
There is a very high bar to get to the same level as cxBladder and very little wriggle room for superiority.
Even so with 800,000 patients being monitored for recurrence several times a year in the US there would be plenty of room for all contenders at the top providing they were able to match cxBladder's performance and prove it.
Getting standard of care status would certainly restrict other contenders for some time to come.
PEB are not ever going to capture the entire market and 10% would probably do nicely for PEBs continued existence, further clinical trials and other product development.
Makes you wonder what the other 90% will be doing in the meantime, doesnt it?
Unfortunately we have had to do the same, greatly reduced our holdings to reduce downside exposure. The risk reward at this time is too great. Makes more sense to sell out, then buy back in once/if there is any real traction and progress with real data/figures. Downside SP trend stronger than any upside potential currently. Don't want to be caught in a large sell off after following update if it is not a substantial uplift (which is unlikely). May well see some likeminded trades and a continued downwards push on SP prior to update.
Bit more to it than just 1700 tests.
Compilation of data requires a number of people working on it firstly to get the numbers signed up and to keep track of them all over several years.
Some patients will pass on, some will be declared in remission, and there is of course the waiting gap between one test and any further test on an individual patient. This is invariably three months but is sometimes longer.
Throw a bit of disruptive Covid amongst everything and yes there could be quite some time involved.
Dangerously close to a breakdown if 0.77 doesn't hold. SP might take a sharp rapid decline if we see this support point fail. Who's got nerves of steel to be holding or even buying at current level!? Must have steady hands
Yes, the hype up before CR, right before DD exit, inflate SP, execute CR at max SP, followed by leaving shareholders behind once capital in the bank and SP erodes away. It's a fine line what is deemed market manipulation. Yet retail traders get contacted by NZX for market manipulation for a few subjectively sensitive trading placements bids/sells. Yep massive manipulation prior to a CR and subsequent fall back is fine. I agree not right for those that bought in on CR. Is on its way to 50% retracement from CR. If that's not classic example of hype and pump announcements prior to a CR then what is defined as market manipulation.
Can but hope 0.77 holds today, but not looking like it is shaping up well, break through below 0.77 will be followed by substantial and rapid retracement. Take caution.
Not at all. Would like to see 0.78 hold, which it looks like it has and a decent rally coming back off today. Even with poor general market uncertainty. Shows resilience forming, lower end trough may be forming at this level. Nice to see a push higher today. Possibly close at 0.85. Which many would welcome a decent relief rally today. More buy demand than sell today. Positive
Any minor SP increase will still be cold comfort to those who participated in the latest CR. The SP will continue to wobble until there is news of some substance from the company.
I think the best we can hope for in the short-term is some positive data in the FY announcement next week such as an increase in test numbers and payments and maybe an update on activity via Kaiser Permanente.
Meantime, it's fingers crossed and hope that Dr. Meintjes is 100% focused on pulling a rabbit out of the hat soon.
Newsletter this morning...:
Snippet...: "...the more than 500 monthly users of Cxbladder products..."...
If a "user" is a patient, it seems very low, but if a "user" is a clinician numbers could be looking promising...!!
Dear Shareholder,
Pacific Edge is pleased to report strong interest in its advanced genomic biomarker Cxbladder tests from the recently-concluded American Urological Association (AUA) Annual Meeting in New Orleans.
The AUA meeting is the biggest event on the US and global urological conference calendar, attracting thousands of urologists, oncologists, researchers, educators, and healthcare professionals and companies from around the world.
Pacific Edge has been a long time and significant sponsor of the AUA and dramatically increased its presence in the main exhibition hall, while also sponsoring key sessions for Veterans Affairs and the newly created “Bladder Cancer Forum”.
The forum, hosted by the research organisation the International Bladder Cancer Group (IBCG) heard expert international panellists across bladder cancer disciplines delivering lectures on contemporary bladder cancer management, as well as treatment strategies in challenging disease states. The forum was moderated by Dr. Ashish Kamat (MD Anderson Cancer Center) and Dr. Sima Porten (UCSF).
Pacific Edge’s CEO, Dr. Peter Meintjes says: “We have been delighted with the interest we have received in Cxbladder at the AUA. Many oncologists expressed a strong desire for advanced genomic biomarkers to break through into the guidelines where simpler biomarkers have under-delivered.
“The performance characteristics established in Pacific Edge’s catalogue of peer-reviewed publications and, the more than 500 monthly users of Cxbladder products and the exciting clinical utility studies roadmap have spurred significant optimism that Cxbladder can address a number of unmet needs in the urological care pathway.
“Ongoing clinical studies continue to demonstrate Cxbladder’s role in facilitating the early detection of urothelial cancer and helping clinicians rule out urothelial cancer for low-risk patients presenting with haematuria, thereby offering opportunities to reduce unnecessary and invasive cystoscopies.
“In the specialist setting, Cxbladder has demonstrated its ability to help clinicians adjudicate diagnostic dilemmas (most commonly equivocal cystoscopy and atypical cytology) to enable earlier detection of tumours and to help treatment prioritisation.
“In the surveillance setting, Cxbladder has been shown to reduce the frequency of surveillance cystoscopy, sparing patients the potential risks, discomfort, and anxiety from cystoscopy, without compromising detection rates. It can also free up resources to be focused on patients most in need and facilitate compliance with cancer surveillance and management regimes.”
The tests are also covered for reimbursement by the Centers for Medicare and Medicaid Services (CMS).
“After two years of COVID affecting such important gatherings, the AUA meeting offers Pacific Edge unmatched opportunities to engage with the clinicians that regularly order Cxbladder tests to assess and manage their patients’ care. Conferences are an ideal forum to engage with clinicians,” says David Levison, Executive Chairman of Pacific Edge’s operations in the US.
“Events such as these take urologists away from the daily pressures of their clinical practice. The relaxed and informal setting gives them opportunities to focus on the latest developments in their field and discuss them with their colleagues and leading clinicians.”
If it were clinicians then it would've said that as that surely...? Mind you each clinician isn't likely to be doing multiple tests a month so whether a user is patient or clinician probably neither here nor there...
Of course a "user" could also be both patient and clinician...